MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ
30.43
-2.11
-6.48%
After Hours: 30.50 +0.07 +0.23% 18:16 04/12 EDT
OPEN
32.28
PREV CLOSE
32.54
HIGH
32.30
LOW
30.02
VOLUME
405.05K
TURNOVER
0
52 WEEK HIGH
43.81
52 WEEK LOW
17.52
MARKET CAP
819.03M
P/E (TTM)
-27.2597
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ARCT last week (0401-0405)?
Weekly Report · 5d ago
Weekly Report: what happened at ARCT last week (0325-0329)?
Weekly Report · 04/01 12:02
Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress
TipRanks · 04/01 11:15
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
TipRanks · 03/26 11:15
Weekly Report: what happened at ARCT last week (0318-0322)?
Weekly Report · 03/25 12:05
Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)
3 analysts have maintained Buy ratings on Enliven Therapeutics, Alphatec Holdings and Arcturus Therapeutic. The 3 stocks are in the Healthcare sector and are expected to make moves following their insider activities. The analyst consensus for each of the 3 stocks is a strong Buy.
TipRanks · 03/20 11:30
Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III
Meiji Holdings has announced the success of the Kostaive® bivalent mRNA COVID-19 vaccine in a Phase III clinical trial for booster vaccination in Japan. This comes after a distribution agreement with influenza vaccine leader Seqirus for the vaccine’s sales in Japan .
TipRanks · 03/19 10:12
Monday's ETF Movers: VOX, XBI
NASDAQ · 03/18 16:03
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Webull offers Arcturus Therapeutics Holdings Inc stock information, including NASDAQ: ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.